Triple Negative Breast Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 66 expanded access programs, clinical trials, and compassionate use pathways listed for Triple Negative Breast Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with triple negative breast cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 20 programs are currently active or recruiting, with the remaining 46 in other lifecycle stages. Sponsors actively running programs in this area include Gilead Sciences, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Genmab, H. Lee Moffitt Cancer Center and Research Institute, and others.
By recruiting status
Snapshot of where every Triple Negative Breast Cancer program currently sits in its lifecycle.
- Active / Recruiting20
- Inactive46
Top sponsors
Organisations running the most Triple Negative Breast Cancer programs in the directory.
- Gilead Sciences4 programs
- Memorial Sloan Kettering Cancer Center4 programs
- Dana-Farber Cancer Institute2 programs
- Genmab2 programs
- H. Lee Moffitt Cancer Center and Research Institute2 programs
- M.D. Anderson Cancer Center2 programs
- Massachusetts General Hospital2 programs
- Providence Health & Services2 programs
- University of Kansas Medical Center2 programs
- A2 Biotherapeutics Inc.1 program
Triple Negative Breast Cancer programs (66)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Emiltatug Ledadotin (Emi-Le) for Patients with Solid Tumors — Day One Biopharmaceuticals, Inc.
- Study on Alternative Dosing of Sacituzumab Govitecan for Advanced Triple-Negative Breast Cancer — Gilead Sciences
- Study of Tetrathiomolybdate (TM) and Capecitabine for High-Risk Triple Negative Breast Cancer — Dartmouth-Hitchcock Medical Center
- Study on the Safety and Effectiveness of A2B395 CAR T-Cell Therapy for Solid Tumors with Specific Genetic Markers — A2 Biotherapeutics Inc.
- Study on the Safety of AZD6750 for Adults with Advanced or Metastatic Solid Tumors — AstraZeneca
- Study on Anthracycline-Free Chemoimmunotherapy Before Surgery for Triple Negative Breast Cancer Patients — Medical University of South Carolina
- Study on Atezolizumab and Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA) — Dana-Farber Cancer Institute
- Study on Carboplatin and Nab-Paclitaxel Before Surgery for Treating Locally Advanced or Inflammatory Triple Negative Breast Cancer — City of Hope Medical Center
- Study on Cisplatin, Romidepsin, and Nivolumab for Locally Recurrent or Metastatic Triple Negative Breast Cancer — Priyanka Sharma
- Study on Chemotherapy with Atezolizumab or Placebo Before and After Surgery for Triple-Negative Breast Cancer — NSABP Foundation Inc
- Study on New Biomarker-Driven Treatments for Advanced Breast Cancer — UNC Lineberger Comprehensive Cancer Center
- Study on Using Enzalutamide for Early Stage Androgen Receptor Positive Triple Negative Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on LN-145 or LN-145-S1 for Treating Patients with Certain Types of Cancer That Have Returned or Not Responded to Treatment — M.D. Anderson Cancer Center
- Study on Chemotherapy and Surgery for Treating Triple Negative Stage II-III Breast Cancer — Rutgers, The State University of New Jersey
- Study on the Safety and Effectiveness of ST-067 in Patients with Advanced Solid Tumors — Simcha IL-18, Inc.
- Phase 2 Study of Weekly Carboplatin and Paclitaxel Before Surgery in Triple Negative Breast Cancer — University of Illinois at Chicago
- Study on Using Stereotactic Body Radiation Therapy (SBRT) for Patients with Metastatic Breast and Lung Cancers — Memorial Sloan Kettering Cancer Center
- Study on Sacituzumab Govitecan and Zimberelimab with Radiation for Treating Metastatic Triple Negative Breast Cancer with Brain Metastases — H. Lee Moffitt Cancer Center and Research Institute
- Study on Standard Chemotherapy Plus Pembrolizumab for Breast Cancer — Providence Health & Services
- Study on SPEDOX-6 for Advanced Cancers — University of California, Irvine
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on TC-510 Cell Therapy for Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
- Study on VLS-1488 for Patients with Advanced Cancer — Volastra Therapeutics, Inc.
- Study on LY2880070 for Patients with Advanced or Metastatic Cancer — Esperas Pharma Inc.
- Study on Navicixizumab Alone or Combined with Other Treatments for Advanced Solid Tumors — OncXerna Theraputics, Inc.
- Study on Radiation Therapy with Pembrolizumab and Olaparib for Women with Certain Types of Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on the Effectiveness and Safety of Nanosomal Docetaxel Lipid Suspension in Patients with Triple Negative Breast Cancer — Jina Pharmaceuticals Inc.
- Study on APL-5125 for Adults with Advanced Solid Tumors — Apollo Therapeutics Ltd
- ARX788 for Treating Patients with HER2-low Advanced or Metastatic Breast Cancer — Laura Huppert, MD, BA
- Study on CAB-ROR2-ADC for Treating Advanced Breast, Head & Neck, Lung Cancer, and Melanoma — BioAtla, Inc.
- Study on Using Circulating Tumor DNA to Guide Post-Surgery Treatment for Patients with Residual Triple Negative Breast Cancer — Bryan Schneider, MD
- Study on How Tumor Shrinkage Before Surgery Relates to Remaining Cancer in Early Breast Cancer Patients — Baylor Breast Care Center
- Study on Using Genomically Guided Radiation Therapy for Treating Triple Negative Breast Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Study on the Impact of Vitamin D Supplements on Cancer Treatment Response in Patients with Vitamin D Deficiency — Wake Forest University Health Sciences
- Study on INCMGA00012 and Pelareorep for Treating Metastatic Triple Negative Breast Cancer (IRENE Study) — Mridula George, MD
- Study on Using Stereotactic Body Radiotherapy (SBRT) with Standard Treatment for Cancer That Has Spread — Memorial Sloan Kettering Cancer Center
- Study on Non-Surgical Treatment Approach for Managing Breast Cancer — Ohio State University Comprehensive Cancer Center
- Study on INBRX-106 and Pembrolizumab as a Chemotherapy-Free Treatment for Stage II Triple Negative Breast Cancer (TNBC) — Providence Health & Services
- Study on Nivolumab and Chemotherapy Before Surgery for Localized Triple-negative Breast Cancer — Washington University School of Medicine
- Study on Pembrolizumab and Chemotherapy Before Surgery for Triple Negative Breast Cancer — University of Kansas Medical Center
- Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC — University of Kansas Medical Center
- Study on NUV-868 Alone and with Olaparib or Enzalutamide for Adults with Advanced Solid Tumors — Nuvation Bio Inc.
- Study on Pembrolizumab with Carboplatin and Paclitaxel Before Surgery for Early Stage Triple Negative Breast Cancer — M.D. Anderson Cancer Center
- Study on PET Scan Guided Treatment for Stage 2 and 3 Triple Negative Breast Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Pre-Surgery Pembrolizumab and Radiation Therapy for Breast Cancer (P-RAD) — Laura M. Spring, MD
- Study on PRO1107 for Patients with Advanced Solid Tumors — Genmab
- Study on ProAgio and Gemcitabine for Patients with Metastatic Triple Negative Breast Cancer — ProDa BioTech, LLC
- Study on Radiation, Immunotherapy, and PARP Inhibitor for Treating Metastatic Triple Negative Breast Cancer — Massachusetts General Hospital
- Study on RAPA-201 Therapy for Solid Tumors — Rapa Therapeutics LLC
- Study on Ribociclib and Bicalutamide for Advanced AR+ Triple-Negative Breast Cancer — Kari Wisinski
- Study on PRO1184 for Advanced Solid Tumors — Genmab
- Study on Sacituzumab Govitecan with or without Pembrolizumab for Treating Metastatic Triple-Negative Breast Cancer — Dana-Farber Cancer Institute
- Study on Sacituzumab Govitecan for Treating Localized Triple Negative Breast Cancer (TNBC) — Massachusetts General Hospital
- Study on Sacituzumab Tirumotecan Plus Pembrolizumab Versus Doctor's Choice Treatment in Triple-Negative Breast Cancer Patients Who Did Not Achieve Complete Response After Initial Therapy — Merck Sharp & Dohme LLC
- Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy — BioNTech SE
- Monitoring Tumor DNA in Blood During Capecitabine Treatment for Early Triple-negative Breast Cancer — Stanford University
- Phase II Study of Carboplatin with or without Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers — Kathy Miller
- Study on BT5528 for Patients with Advanced Solid Tumors Linked to EphA2 Expression — BicycleTx Limited
- Study on Adagloxad Simolenin (OBI-822)/OBI-821 for Treating Globo H Positive Triple-Negative Breast Cancer — OBI Pharma, Inc
- Study of BDC-3042 Alone and with Cemiplimab in Patients with Advanced Cancers — Bolt Biotherapeutics, Inc.
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Gilead Sciences
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Doctor's Choice Treatment in Patients with Triple Negative Breast Cancer with Remaining Disease After Surgery and Pre-Surgery Therapy — Gilead Sciences
- Study Comparing Sacituzumab Govitecan-hziy to Doctor's Choice Treatment for Advanced or Metastatic Triple-Negative Breast Cancer — Gilead Sciences
- Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas — Immunitas Therapeutics
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Study on ZN-c3, Carboplatin, and Pembrolizumab for Metastatic Triple-Negative Breast Cancer — Filipa Lynce, MD
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Triple Negative Breast Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.